Non-surgical Treatment of Peri-implant Pockets With H42 (H42)

July 1, 2026 updated by: Bioteck S.p.A.

This prospective, observational study evaluates the efficacy and safety of H42 non-surgical treatment for peri-implant pockets. The trial involves 56 patients, with 28 subjects receiving the H42 treatment and 28 acting as a control group to monitor soft tissue healing and bone level changes.

Clinical outcomes focus on Pocket Probing Depth (PPD) and Silness and Löe Plaque Index (PI) measured at baseline, 1 month, and 3 months. Gingival inflammation, pain intensity on a 0-10 NRS scale, and absence of infection are monitored at baseline, 7, 14, and 21 days, and at 1 and 3 months. Additionally, a five-point tissue assessment evaluates color, suppuration, granulation tissue, bleeding, and incision margins. Radiographic analysis at baseline and 3 months uses standardized periapical x-rays to measure bone level, intra-bony defect height, width, and angulation. Safety is assessed through the continuous registration of adverse events.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

56

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Spain
      • Seville, Spain, 41009
        • Recruiting
        • Faculty of Dentistry, University of Seville
        • Contact:
          • Guillermo Machuca-Portillo, MD
          • Phone Number: +34 954481128
          • Email: gmachuca@us.es

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Adult patients diagnosed with peri-implantitis and treated at the Department of Stomatology, Faculty of Dentistry, University of Seville, Spain. Participants are recruited from patients seeking care at the university dental clinic and are allocated to the study groups according to the study protocol and predefined inclusion and exclusion criteria. The study evaluates the adjunctive use of H42 hydrogel in the non-surgical treatment of peri-implantitis using a case-control design.

Description

Inclusion Criteria:

  • Men or women with age ≥ 25 and ≤ 65 years.
  • Subjects affected by peri-implant pockets with probing depth (PD) in the range between 6 to 8 mm.
  • Each subject can have from 1 to 5 defects.
  • Subjects willing to provide signed informed consent to clinical investigation participation.

Exclusion Criteria:

  • Use of aspirin and antiplatelet agents a week before treatment.
  • Subjects smokers ≥ 10 cigarettes per day.
  • Subjects presenting current or previous bleeding disorders.
  • Subjects taking or having indications for anticoagulant therapy.
  • Concomitant treatments or procedures to improve gum health over the last six months before the clinical investigation enrolment, such as HA gel treatments, injection of fillers, and surgery.
  • Subjects suffering from infectious diseases, including herpes simplex infection, active hepatitis, or human immunodeficiency virus.
  • Subjects with dental aesthetic surgery in the preceding 12 months before the clinical investigation enrolment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
H42 treated group
28 patients treated with ultrasonic treatment and manual curettes + H42®
Control group
28 patients only with ultrasonic treatment and manual curettes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pocket Probing Depth (PPD)
Time Frame: At 1 month and 3 months in comparison with the baseline value
The distance measured from the base of the pocket to the most apical point on the gingival margin, and it will be measured with an electronic Florida probe at controlled pressure
At 1 month and 3 months in comparison with the baseline value
Plaque Index (PI)
Time Frame: At 1 month and 3 months in comparison with the baseline
For each tooth, the four-point scale Silness and Löe Plaque Index is used (Score 0: Excellent; 3: poor)
At 1 month and 3 months in comparison with the baseline
Degree of inflammation
Time Frame: Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Not inflamed, mild inflamed, Moderately inflamed, Very inflamed
Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
NRS scale
Time Frame: Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Numeric Rating Scale is a simple, reliable tool used to measure pain intensity on a scale from 0 to 10 (0: no pain; 10: maximum pain)
Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Absence of infection
Time Frame: Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Clinical evaluation to assess the absence of infection, specifically defined as the absence of suppuration (pus formation), at the treated site as evaluated by the Investigator.
Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tissue assessment
Time Frame: Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Color, suppuration, granulation tissue, bleeding on palpation and incision margins on a five-point scale: 1 is very poor, 2 is poor, 3 is good, 4 is very good, and 5 is excellent
Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Radiographic image (x-ray)
Time Frame: Baseline and 3 months follow-up
Periapical radiographs were taken using the parallel long cone technique using a customized film-holder device and a bite block. - Bone level (BL): distance (mm) between the implant shoulder and the base of the defect.
Baseline and 3 months follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bioteck S.p.A.

Collaborators

University of Seville

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 3, 2025

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

June 24, 2026

First Submitted That Met QC Criteria

July 1, 2026

First Posted (Actual)

July 2, 2026

Study Record Updates

Last Update Posted (Actual)

July 2, 2026

Last Update Submitted That Met QC Criteria

July 1, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 250423_H42_general

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peri-implantitis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe